IMVT Stock Immunovant, Inc.
BUY US · NasdaqGSRecent share offering attracted insider buying, improving risk-reward into upcoming data.
Future value: $48.88 (+73.50%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Post-offering insider buying supports the stock.
- ▾Below 50-day MA (-21.23%)
- ▸~74% upside to price target
Is IMVT a buy right now?
Trend: IMVT is trading below the 50-day average (-21.22%), RSI 41 — neutral momentum, with a 3-month return of -27.58%.
Valuation & quality: Immunovant, Inc. trades on forward P/E -10.2, price-to-book 7.90; fundamentals show net margin 0.0%, return on equity -80.1%.
Analyst consensus: 16 analysts have a mean 12-month price target of $48.88 (+73.5% vs the last close; range $30.00 – $66.00), consensus rating “buy”.
Our screen: BUY (score 2) — Recent share offering attracted insider buying, improving risk-reward into upcoming data.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -10.40% | +9.30% | +22.70% | +15.70% | +0.20% | +5.70% | -17.20% | -16.60% |
Fundamentals
Analyst price target
Technical signals
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
Sector: Healthcare · Industry: Biotechnology · United States · 315 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.